Difference between revisions of "Bone sarcoma"
Jump to navigation
Jump to search
m |
|||
| Line 39: | Line 39: | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
| − | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010] | + | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext Thomas et. al 2010 (Amgen 20040215)] |
| − | |style="background-color:#91cf61"|Phase II | + | |style="background-color:#91cf61"|Phase II (RT) |
| + | |- | ||
| + | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70277-8/fulltext Chawla et al. 2013 (Amgen 20062004)] | ||
| + | |style="background-color:#91cf61"|Phase II (RT) | ||
|- | |- | ||
|} | |} | ||
| Line 55: | Line 58: | ||
===References=== | ===References=== | ||
| − | # Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20149736 PubMed] | + | # '''Amgen 20040215:''' Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70010-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20149736 PubMed] |
| + | # '''Amgen 20062004:''' Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70277-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23867211 PubMed] | ||
| + | ## '''Update:''' Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30663-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/31704134 PubMed] | ||
=Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy= | =Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy= | ||
Revision as of 03:18, 29 January 2020
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN  ejdavis25
|
0 regimens on this page
0 variants on this page
|
Note: this page is for subtype-nonspecific bone sarcoma regimens, and some subtypes with very few subtype-specific regimens. Please see the category page for links to other sarcoma types or use one of these links:
Guidelines
ESMO
NCCN
Chondrosarcoma, all lines of therapy
- No standard chemotherapy for grades 1 to 3 conventional chondrosarcoma
- Mesenchymal chondrosarcoma has been treated with Ewing's sarcoma regimens
- Dedifferentiated chondrosarcoma has been treated with osteosarcoma regimens
Giant-cell tumor of bone, all lines of therapy
Denosumab monotherapy
| back to top |
Regimen
| Study | Evidence |
|---|---|
| Thomas et. al 2010 (Amgen 20040215) | Phase II (RT) |
| Chawla et al. 2013 (Amgen 20062004) | Phase II (RT) |
Chemotherapy
- Denosumab (Xgeva) as follows:
- Cycle 1: 120 mg SC once per day on days 1, 8, 15
- Cycle 2 onwards: 120 mg SC once on day 1
Supportive medications
- Calcium 500 mg PO once per day
- Vitamin D 400 IU PO once per day
28-day cycles
References
- Amgen 20040215: Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010 Mar;11(3):275-80. link to original article contains verified protocol PubMed
- Amgen 20062004: Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013 Aug;14(9):901-8. Epub 2013 Jul 16. link to original article contains protocol PubMed
- Update: Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. Epub 2019 Nov 6. link to original article PubMed
Malignant fibrous histiocytoma (MFH) of bone, all lines of therapy
- Malignant fibrous histiocytoma (MFH) of bone has been treated with osteosarcoma regimens